Ling‐Yuh Huw

996 total citations
26 papers, 654 citations indexed

About

Ling‐Yuh Huw is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ling‐Yuh Huw has authored 26 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ling‐Yuh Huw's work include Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Ling‐Yuh Huw is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Ling‐Yuh Huw collaborates with scholars based in United States, Canada and Switzerland. Ling‐Yuh Huw's co-authors include Mark R. Lackner, Lukas C. Amler, Katalin Kauser, Keith R. Willison, Karen Artzt, Yulei Wang, Andrew S. Goldsborough, Michael C. Wei, Jill M. Spoerke and Hartmut Koeppen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Ling‐Yuh Huw

25 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ling‐Yuh Huw United States	15	273	254	154	142	82	26	654
Zorka Milovanović Serbia	17	261 1.0×	241 0.9×	51 0.3×	119 0.8×	162 2.0×	55	707
Xianyu Zhang China	17	295 1.1×	649 2.6×	143 0.9×	307 2.2×	60 0.7×	52	1.0k
Giuseppe Nicolò Fanelli Italy	14	237 0.9×	209 0.8×	88 0.6×	198 1.4×	70 0.9×	46	630
Run-Fen Cheng China	16	204 0.7×	425 1.7×	54 0.4×	168 1.2×	55 0.7×	38	757
Matthew Dankner Canada	12	374 1.4×	390 1.5×	152 1.0×	119 0.8×	90 1.1×	29	747
Nobue Kumaki Japan	14	300 1.1×	135 0.5×	85 0.6×	201 1.4×	86 1.0×	47	600
Yunxiao Meng China	17	261 1.0×	510 2.0×	83 0.5×	339 2.4×	70 0.9×	32	909
M. Herman Chui United States	17	307 1.1×	352 1.4×	215 1.4×	197 1.4×	56 0.7×	50	964
Andreas Schnelzer Germany	13	338 1.2×	525 2.1×	72 0.5×	185 1.3×	47 0.6×	28	1.1k
Yul Ri Chung South Korea	21	492 1.8×	426 1.7×	132 0.9×	497 3.5×	122 1.5×	48	1.1k

Countries citing papers authored by Ling‐Yuh Huw

Since Specialization

Citations

This map shows the geographic impact of Ling‐Yuh Huw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling‐Yuh Huw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling‐Yuh Huw more than expected).

Fields of papers citing papers by Ling‐Yuh Huw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling‐Yuh Huw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling‐Yuh Huw. The network helps show where Ling‐Yuh Huw may publish in the future.

Co-authorship network of co-authors of Ling‐Yuh Huw

This figure shows the co-authorship network connecting the top 25 collaborators of Ling‐Yuh Huw. A scholar is included among the top collaborators of Ling‐Yuh Huw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling‐Yuh Huw. Ling‐Yuh Huw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Chi‐Chung, Chi‐Chung Li, Brendan C. Bender, et al.. (2024). A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical Pharmacology & Therapeutics. 117(2). 465–474. 3 indexed citations

Li, Chi‐Chung, Kapil Gadkar, Genevive Hernandez, et al.. (2023). Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and Translational Science. 16(7). 1134–1148. 44 indexed citations

Schuster, Stephen J., Ling‐Yuh Huw, Christopher R. Bolen, et al.. (2023). Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 143(9). 822–832. 34 indexed citations

Wang, Michael, Sarit Assouline, Manali Kamdar, et al.. (2023). Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study. Blood. 142(Supplement 1). 734–734. 18 indexed citations

Johnson, Radia Marie, Xueping Qu, Ling‐Yuh Huw, et al.. (2022). ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications. 13(1). 5478–5478. 24 indexed citations

Olszewski, Adam J., Lihua E. Budde, Nilanjan Ghosh, et al.. (2022). Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study. Blood. 140(Supplement 1). 3757–3759. 12 indexed citations

Mascarenhas, John, Francesco Passamonti, Kate Burbury, et al.. (2021). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances. 6(4). 1162–1174. 16 indexed citations

Palomba, Maria Lia, Guillaume Cartron, Leslie Popplewell, et al.. (2021). Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clinical Lymphoma Myeloma & Leukemia. 22(7). 504–512. 29 indexed citations

Budde, Lihua E., Nilanjan Ghosh, Julio C. Chávez, et al.. (2021). Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).. Journal of Clinical Oncology. 39(15_suppl). 7520–7520. 14 indexed citations

10.

Johnson, Radia Marie, Xueping Qu, Joshua D. Thomas, et al.. (2020). Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC. Cancer Research. 80(16_Supplement). LB–63. 2 indexed citations

11.

Chen, Xiaoji, Ching‐Wei Chang, Jill M. Spoerke, et al.. (2019). Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. Clinical Cancer Research. 25(7). 2254–2263. 54 indexed citations

12.

Raval, Aparna, Hearn Jay Cho, Mark Yan, et al.. (2019). Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1907–1907. 2 indexed citations

13.

Hernandez, Genevive, Ling‐Yuh Huw, Anton Belousov, et al.. (2019). Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1585–1585. 11 indexed citations

14.

Wilson, Timothy R., Jianjun Yu, Xuyang Lu, et al.. (2016). The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. npj Breast Cancer. 2(1). 16022–16022. 25 indexed citations

15.

Makker, Vicky, Fernando O. Recio, Ling Ma, et al.. (2016). A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 122(22). 3519–3528. 64 indexed citations

16.

Ryner, Lisa, Yinghui Guan, Ron Firestein, et al.. (2015). Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research. 21(13). 2941–2951. 86 indexed citations

17.

Zha, Jiping, Carol O’Brien, Heidi Savage, et al.. (2009). Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Molecular Cancer Therapeutics. 8(8). 2110–2121. 66 indexed citations

18.

Qian, Hu Sheng, Christian Beauséjour, Ling‐Yuh Huw, et al.. (2006). Age-Dependent Acceleration of Ischemic Injury in Endothelial Nitric Oxide Synthase-Deficient Mice: Potential Role of Impaired VEGF Receptor 2 Expression. Journal of Cardiovascular Pharmacology. 47(4). 587–593. 18 indexed citations

19.

Wang, Yi-Xin, Baby Martin-McNulty, Ling‐Yuh Huw, et al.. (2002). Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 162(1). 23–31. 70 indexed citations

20.

Huw, Ling‐Yuh, Andrew S. Goldsborough, Keith R. Willison, & Karen Artzt. (1995). Tctex2: A Sperm Tail Surface Protein Mapping to the t-Complex. Developmental Biology. 170(1). 183–194. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact